Bristol-Myers Squibb, a global biopharmaceutical company, has appointed Charles Bancroft as acting chief financial officer (CFO) and announced that Jean-Marc Huet, executive vice president and CFO, will leave the company at the end of 2009.
Bancroft was most recently vice president, finance for Bristol-Myers Squibb’s global biopharmaceutical business. In his new role, Bancroft will continue to report to Lamberto Andreotti, president and chief operating officer (COO).
Bancroft joined Bristol-Myers in 1984 and has since held positions of increasing responsibility within the finance organisation, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec. He received his BS in Accounting from Drexel University, his MBA in Finance from Temple University, and is a certified public accountant (CPA).
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.